Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
K. M. Salim Andalib, Md Habibur Rahman & Ahsan Habib. (2023) Bioinformatics and cheminformatics approaches to identify pathways, molecular mechanisms and drug substances related to genetic basis of cervical cancer. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-16.
Read now
Read now
Sabyasachi Mukhopadhyay, Arpita Maitra & Shouvik Choudhury. (2021) Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. Current Medical Research and Opinion 37:5, pages 789-794.
Read now
Read now
Evgeny N. Imyanitov, Evgeny V. Levchenko, Ekatherina S. Kuligina & Sergey V. Orlov. (2020) Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. Expert Opinion on Pharmacotherapy 21:16, pages 1943-1953.
Read now
Read now
Articles from other publishers (24)
Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria M. Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew, Robert A. Svoboda, Kurt W. Fisher, Robert E. Lewis & Robert L. Kortum. (2023) SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proceedings of the National Academy of Sciences 120:47.
Crossref
Crossref
Sonam Mishra, Niraj Rajput, Tarang Jadav, Niraj Kumar Panday, Amit Kumar Sahu & Pinaki Sengupta. (2023) Delineation of prototypical degradation mechanism, characterization of unknown degradation impurities by liquid chromatography–quadrupole‐time‐of‐flight–tandem mass spectrometry and stability‐indicating analytical method of selumetinib. Biomedical Chromatography.
Crossref
Crossref
Elisabetta Kuhn, Federica Natacci, Massimo Corbo, Luigi Pisani, Stefano Ferrero, Gaetano Bulfamante & Donatella Gambini. (2023) The Contribution of Oxidative Stress to NF1-Altered Tumors. Antioxidants 12:8, pages 1557.
Crossref
Crossref
Anastasios Stathis, Anthony W. Tolcher, Judy S. Wang, Daniel J. Renouf, Lin-Chi Chen, Leah H. Suttner, Tomoko Freshwater, Andrea L. Webber, Tapan Nayak & Lillian L. Siu. (2023) Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors. Investigational New Drugs 41:3, pages 380-390.
Crossref
Crossref
Vikas Sharma & Mohit Gupta. (2022) Designing of kinase hinge binders: A medicinal chemistry perspective. Chemical Biology & Drug Design 100:6, pages 968-980.
Crossref
Crossref
Dia Advani, Sudhanshu Sharma, Smita Kumari, Rashmi K. Ambasta & Pravir Kumar. (2022) Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 433-468.
Crossref
Crossref
Fang-Liang HuangSheng-Jie YuEn-Chih LiaoLong-Yuan LiPei-Wen ShenChia-Ling Li. (2021) Niclosamide suppresses T‑cell acute lymphoblastic leukemia growth through activation of apoptosis and autophagy. Oncology Reports 47:2.
Crossref
Crossref
Shafia Rahman, Shimon Garrel, Michael Gerber, Radhashree Maitra & Sanjay Goel. (2021) Therapeutic Targets of KRAS in Colorectal Cancer. Cancers 13:24, pages 6233.
Crossref
Crossref
Thais Cristina Mendonça Nogueira & Marcus Vinicius Nora de Souza. (2021) New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications. Bioorganic & Medicinal Chemistry 46, pages 116340.
Crossref
Crossref
Sinead M. O’Donovan, Ali Imami, Hunter Eby, Nicholas D. Henkel, Justin Fortune Creeden, Sophie Asah, Xiaolu Zhang, Xiaojun Wu, Rawan Alnafisah, R. Travis Taylor, James Reigle, Alexander Thorman, Behrouz Shamsaei, Jarek Meller & Robert E. McCullumsmith. (2021) Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach. Scientific Reports 11:1.
Crossref
Crossref
Aladdin M. Srour, Nesreen S. Ahmed, Somaia S. Abd El-Karim, Manal M. Anwar & Salwa M. El-Hallouty. (2020) Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Bioorganic & Medicinal Chemistry 28:18, pages 115657.
Crossref
Crossref
Karen Aughton, Haleh Shahidipour, Luna Djirackor, Sarah E. Coupland & Helen Kalirai. (2020) Characterization of Uveal Melanoma Cell Lines and Primary Tumor Samples in 3D Culture. Translational Vision Science & Technology 9:7, pages 39.
Crossref
Crossref
Stefan Naulaerts, Michael P. Menden & Pedro J. Ballester. (2020) Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles. Biomolecules 10:6, pages 963.
Crossref
Crossref
Fang‑Liang HuangEn‑Chih LiaoChia‑Ling LiChung‑Yang YenSheng‑Jie Yu. (2020) Pathogenesis of pediatric B‑cell acute lymphoblastic leukemia: Molecular pathways and disease treatments (Review). Oncology Letters 20:1, pages 448-454.
Crossref
Crossref
Junting Zhou, Xueyang Jiang, Siyu He, Hongli Jiang, Feng Feng, Wenyuan Liu, Wei Qu & Haopeng Sun. (2019) Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. Journal of Medicinal Chemistry 62:20, pages 8881-8914.
Crossref
Crossref
Puranik Purushottamachar, Senthilmurugan Ramalingam & Vincent C.O. Njar. 2019. Chemistry and Applications of Benzimidazole and its Derivatives. Chemistry and Applications of Benzimidazole and its Derivatives.
Colleen M. Cebulla, Bongsu Kim, Valerie George, Tyler Heisler-Taylor, Sumaya Hamadmad, Alana Y. Reese, Shaili S. Kothari, Rania Kusibati, Hailey Wilson & Mohamed H. Abdel-Rahman. (2019) Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment. Investigative Opthalmology & Visual Science 60:1, pages 349.
Crossref
Crossref
Parag P. Patwardhan, Elgilda Musi & Gary K. Schwartz. (2018) Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Molecular Cancer Therapeutics 17:11, pages 2329-2340.
Crossref
Crossref
Md. Jawaid Akhtar, Ahsan Ahmed Khan, Zulphikar Ali, Rikeshwer Prasad Dewangan, Md. Rafi, Md. Quamrul Hassan, Md. Sayeed Akhtar, Anees Ahmad Siddiqui, Sangh Partap, Santosh Pasha & M. Shahar Yar. (2018) Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors. Bioorganic Chemistry 78, pages 158-169.
Crossref
Crossref
Víctor López-Dávila, Tarig Magdeldin, Hazel Welch, Miriam Victoria Dwek, Ijeoma Uchegbu & Marilena Loizidou. (2016)
Efficacy of DOPE/DC-cholesterol liposomes and GCPQ micelles as AZD6244 nanocarriers in a 3D colorectal cancer
in vitro
model
. Nanomedicine 11:4, pages 331-344.
Crossref
Crossref
Zhishan Cui, Xi Li, Lulu Li, Bin Zhang, Chunmei Gao, Yuzong Chen, Chunyan Tan, Hongxia Liu, Weiyi Xie, Ti Yang & Yuyang Jiang. (2016) Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment. Bioorganic & Medicinal Chemistry 24:2, pages 261-269.
Crossref
Crossref
Antoine Muchir & Howard J. Worman. 2016. Intermediate Filament Proteins. Intermediate Filament Proteins
557
580
.
Jin-Hang Gao, Chun-Hui Wang, Huan Tong, Shi-Lei Wen, Zhi-Yin Huang & Cheng-Wei Tang. (2015) Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. Scientific Reports 5:1.
Crossref
Crossref
Soumen Khatua, Jason Wang & Veena Rajaram. (2015) Review of low-grade gliomas in children?evolving molecular era and therapeutic insights. Child's Nervous System 31:5, pages 643-652.
Crossref
Crossref